Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥134.00 - ¥340.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)735.87K
Market Cap
¥2.97B
Enterprise Value¥1.13B
Total Cash (Recent Filing)¥1.59B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-48.09
Shares Outstanding18,429,500
10 Day Avg. Volume162,590
30 Day Avg. Volume735,869
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue has nearly doubled across the reported period, demonstrating sustained commercial expansion and growing customer or product demand. Continued top-line growth can improve operating leverage over time and provides a larger base from which the company may eventually build durable profitability.
Debt-Free Balance SheetThe absence of reported debt limits interest obligations and refinancing exposure, giving management greater flexibility while the business works to improve profitability. A conservatively levered balance sheet also provides more resilience against operating volatility than a similarly loss-making company carrying substantial borrowings.
Positive Asset And Equity BasePositive equity and substantial assets provide an existing financial base to support operations and investment. Although the asset base has weakened over time, retaining positive net worth offers more balance-sheet capacity than a company already operating with negative equity or an impaired capital structure.
Bears Say
Persistent Operating LossesLarge recurring EBIT and net losses indicate that revenue growth has not yet translated into a viable earnings model. Until operating expenses become better aligned with sales, the company remains exposed to continued value destruction and has limited ability to fund expansion through internally generated profits.
Ongoing Cash BurnPersistent negative operating and free cash flow shows that the business consumes cash even as revenue expands. This weakens financial self-sufficiency and could require external funding unless losses narrow materially, potentially limiting strategic flexibility and increasing reliance on capital availability.
Declining Shareholder EquityThe substantial reduction in equity over the reported period signals that accumulated losses are eroding the company’s capital base. Continued deterioration would reduce balance-sheet resilience, constrain resources available for growth, and weaken the long-term returns available to shareholders.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥134.00 and its highest was ¥340.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥2.97B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Nov 13, 2026 which is in 38 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Aug 13, 2026. The company reported -¥11.85 earnings per share for the quarter.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 18,429,500 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.85 in its last earnings report. Following the earnings report the stock price went up 2.797%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―